NCT05683977: ARSENAL

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

Active, enrolled Last updated 24 February 2026

What this trial tests

trial testing durvalumab in Small Cell Lung Carcinoma in 254 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 November 2022

Primary endpoint
1 March 2027

1 March 2027

Quick facts

Lead sponsor	AstraZeneca
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	254
Start date	14 November 2022
Primary completion	1 March 2027
Estimated completion	1 March 2027
Sites	34 locations across France

Drugs / interventions tested

• durvalumab — full drug profile →

Conditions studied

• Small Cell Lung Carcinoma — all drugs for Small Cell Lung Carcinoma →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer. In 2021, an estimated 2.3 million people around the world are diagnosed with lung cancer. In France, in 2018, with 46 363 new cases and 33 117 deaths, lung cancer represented the second most common cancer and the first cause of death from cancer. Among those, SCLC represented 10,8% of all new lung diagnosis, and about two thirds presented at the extensive stage (ES-SCLC).

Since last three decades, standard treatment in ES-SCLC is based on combination chemotherapy with a platinum agent and etoposide in first-line with or without concurrent radiation therapy. Then, the second-line of treatment is topotecan, with few results in terms of response rates and survival rate. However, the emergence of immune checkpoint inhibitors targeting the programmed cell death receptor-1 (PD-1)/PD-ligand 1 (PD-L1) pathway, having an important role in immune regulation became an alternative method in the management and care of disease. Indeed, recent studies have shown an overall survival (OS) benefit for patients with ES-SCLC treated in first line with a combination of platinum-etoposide and immune checkpoint inhibitors. Atezolizumab (Tecentriq®, Roche) and durvalumab (Imfinzi®, AstraZeneca), two anti-Programmed death-ligand 1 (PD-L1) antibodies, delivered positive phase III results, respectively through the Impower-133 and CASPIAN studies, and were granted European market authorisations.

Durvalumab is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with ES-SCLC. On March 10, 2020 French health authorities allowed durvalumab utilization in this setting through a national "early access program" (Autorisation Temporaire d'Utilisation "de cohorte" - ATUc), thus preceding the European market authorization (August 28, 2020). Since 2020 October 1st, durvalumab is used as a post ATU treatment. Since 2020, French AURA treatment guidelines for SCLC have referenced durvalumab in combination with chemotherapy as a first-line treatment option for patients with ES-SCLC.

Whereas the safety and efficacy of the durvalumab have been evaluated in a clinical trial, data are required to further evaluate the use of durvalumab in real-life condition and in less selected population than in clinical trials.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.